Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8Gastrointestinal 8Other hematologic neoplasm 5Myeloid 3Lymphoid 2Tumor-Agnostic 1Other solid neoplasm 1Other neoplasm 1Dermatologic 1Classical hematology 1Breast 1

Conditions

Solid Tumor Cancer 1

Interventions

Injections 54pembrolizumab 40Carboplatin 20Bevacizumab 19Cyclophosphamide 17toripalimab 14Nivolumab 14Cisplatin 14tislelizumab 13fludarabine 13Specimen Handling 13Paclitaxel 13Interviews as Topic 13Pemetrexed 12Standard of Care 11Practice Guidelines as Topic 11Oxaliplatin 11Fluorouracil 10Cetuximab 10atezolizumab 9Educational Status 9Docetaxel 9Capecitabine 9Leucovorin 8Methods 7Etoposide 7Early Intervention, Educational 7spartalizumab 6olaparib 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Imatinib Mesylate × Other solid neoplasm × Clear all
NCT06962254 2025-05-08

Imatinib and Trametinib for KRAS-mutated Solid Tumor

China Medical University Hospital

Phase 1 Recruiting
10 enrolled
Other solid neoplasm

Solid Tumor Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡